Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

Friedeberg brings more than 16 years of experience in economic development, having previously held leadership roles with the ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (BMV:GMED) from Buy to Neutral. There are 759 funds or institutions reporting positions in Globus Medical.

NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are ...

In trading on Friday, shares of Globus Medical Inc (Symbol: GMED) entered into oversold territory, hitting an RSI reading of 23.1, after changing hands as low as $54.75 per share. By comparison ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors ...